ALTMAN STEVEN R 4

What Happened

• Steven R. Altman, a director of DexCom, Inc. (DXCM), received a grant of 5,565 restricted stock units (RSUs) on May 28, 2026. The award was granted with a $0 purchase price (total consideration reported $0). Each RSU represents a contingent right to one share of DexCom common stock upon settlement.

Key Details

• Transaction date: 2026-05-28; SEC filing date: 2026-06-01.
• Grant: 5,565 RSUs; reported acquisition price: $0.00; total cash consideration: $0.
• Vesting: 100% of the RSU award vests on the earlier of the one-year anniversary of the grant (May 28, 2027) or DexCom’s 2027 Annual Meeting of Stockholders (per footnote F1).
• Shares are held by the Steven R. and Lisa J. Altman, TTEE's Altman Family Trust DTD 8/21/92; the reporting person is a trustee (footnote F2).
• Exhibit noted: Exhibit 24 — Power of Attorney. The filing does not state post-transaction total shares beneficially owned.

Context

• This was an equity award (grant), not an open-market purchase or sale. RSU grants are a form of compensation and do not require cash outlay at grant; value is realized only if/when the RSUs vest and are settled into shares.
• Such grants are routine corporate compensation and do not by themselves indicate the director’s personal buying or selling sentiment.